ADT	androgen deprivation therapy
AE	adverse events
AIF	apoptosis-inducing factor
ALT	alanine aminotransferase
APE1/Ref-1	apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1
AST	aspartate aminotransferase
AUC	area under the concentration time curve
BID	latin: bis in die; twice a day
Bcl-2	B-cell lymphoma 2
BH3	Bcl-2 homology domain 3
CEA	carcinoembryonic antigen
CHD1	chromodomain helicase DNA-binding protein
co	control
cCR	clinical complete response
CR	complete response
CRPC	castrate-resistant prostate cancer
CTCAE	Common Terminology Criteria for Adverse Events
CXCL8	chemokine C-X-C motif ligand 8
DCR	disease control rate
DLT	dose-limiting toxicity
DNA	deoxyribonucleic acid
ECG	electrocardiogram
ECOG	Eastern Cooperative Oncology Group
eg	experimental group
EGFR	epidermal growth factor receptor
ES-SCLC	extensive stage—small cell lung cancer
GEC	gastroesophageal carcinoma
GI	gastrointestinal
HDAC	histone deacetylase
HDACi	histone deacetylase inhibitor
HNSCC	head and neck squamous cell carcinoma
IL-8	interleukin-8
IV	intravenously
LHRH	luteinizing hormone-releasing hormone
MOMP	mitochondrial outer membrane permeabilization
mOS	median overall survival
mPFS	median progression-free survival
MR	minor response
MTD	maximally tolerated dose
n. a.	not available
ORR	objective response rate
OR	objective response
OS	overall survival
P-gp	p-glycoprotein
PBMC	peripheral blood mononuclear cell
PCWG	Prostate Cancer Clinical Trials Working Group
PD	progressive disease
PFS	progression-free survival
PO BID	latin: per os bis in die; orally, twice a day
PO QD	latin: per os quaque die; orally, once a day
PR	partial response
PSA	prostate-specific antigen
R/M	recurrent/metastatic
Rb	retinoblastoma protein
RECIST	response evaluation criteria in solid tumors
ROS	reactive oxygen species
RR	response rate
SAE	serious adverse event
SCLC	small cell lung cancer
SD	stable disease
SOX9	SRY-box transcription factor 9
SWOG	Southwestern Oncology Group
VEGF	vascular endothelial growth factor
YAP1	yes-associated protein 1